Pasithea Therapeutics Corp. (KTTA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US70261F2020
Pasithea Therapeutics Corp. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -20.86 m USD |
| EBIT | -20.75 m USD |
| Net income | -20.43 m USD |
| Diluted EPS – continuing operations | -2.91 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
More stocks
- REED'S, INC. (REED)
- AYTU BIOPHARMA, INC (AYTU)
- FULL HOUSE RESORTS INC (FLL)
- SRX Global Inc. (SRXH)
- Big Digital Energy, Inc. (BGDE)
- FTC Solar, Inc. (FTCI)
- NextPlat Corp (NXPL)
- Annovis Bio, Inc. (ANVS)
- Nexscient, Inc. (NXNT)
- Lipocine Inc. (LPCN)
- Motorsport Games Inc. (MSGM)
- Cocrystal Pharma, Inc. (COCP)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.